___

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics. Ca-Cancer J Clin. 2008;58:71–96.
• Kelly KM, Shah N, Shedlosky-Shoemaker R, Porter K, Agnese D. Living post treatment: Definitions of those with history and no history of cancer. J. Cancer Surv. 2011;5:158–66.
• Taby R, Issa JP. Cancer epigenetics. Ca Cancer J Clin. 2010;60:376–92.
• Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010;12(Suppl 2):S1.
• Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28:3366–79.
• Esteller M, Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8:286–98.
• Handel AE, Ebers GC, Ramagopalan SV. Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med. 2010;16:7–16.
• Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63.
• Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. Conversion of 5- methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–5.
• Robertson AB, Dahl JA, Vågbø CB, Tripathi P, Krokan HE, Klungland A. A novel method for the efficient and selective identification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. 2011;39:55.
• Voso MT, D’Alò F, Greco M, Fabiani E, Criscuolo M, Migliara G et al. Epigenetic changes in therapy- related MDS/AML. Chem Biol Interact. 2010;184:46-9.
• Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci. 2011;68:1681–702.
• Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9:2395–402.
• Schaefer M, Hagemann S, Hanna K, Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res. 2009;69:8127–32.
• Chen ZX, Riggs AD. DNA methylation and demethylation in mammals. J Biol Chem. 2011;286:18347–53.
• Gehring M, Reik W, Henikoff S. DNA demethylation by DNA repair. Trends Genet. 2009;25:82–90.
• Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res. 2008;647:44–51.
• Krawczyk B. Fabianowska-Majewska K. Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues. Nucleos Nucleot Nucleic Acids. 2006;25:1029–32.
• Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol. 2009;49:243–63.
• Chik F, Szyf M. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis. 2011;32:224–32.
• Mabaera R, Greene MR, Richardson CA, Conine SJ, Kozul CD, Lowrey CH. Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine’s ability to induce human fetal hemoglobin. Blood. 2008;111:411–20.
• Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483-95.
• Kuo HK, Griffith JD, Kreuzer KN. 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res. 2007;67:8248–54.
• Gaffari A. Kemoterapotiklerin erkek üreme sistemi üzerindeki yan etkileri ve koruyucu stratejiler. Marmara Pharmaceutical Journal. 2013;17:73-92.
• Li Q, Bartlett DL, Gorry MC, O’Malley ME, Guo ZS. Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol. 2009;76:1072–81.
• Qu Z, Fu J, Yan P, Hu J, Cheng SY, Xiao G. Epigenetic repression of PDZ-LIM domain-containing protein 2: Implications for the biology and treatment of breast cancer. J Biol Chem. 2010;285:11786–92.
• Xu J, Zhou JY, Tainsky MA, Wu GS. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 2007;67:1203–11.
• Mirza S, Sharma G, Pandya P, Ralhan R. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Mol Cell Biochem. 2010;342:101–9.
• Bolaman A. Miyelodisplastik sendromda hedefe yönelik tedaviler. Turkiye Klinikleri J Hematol- Special Topics. 2014;7:17-23.
• Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) Cancer Chemother Pharmacol. 2008;62:363–68.
• Gowher H, Jeltsch A. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther. 2004;3:1062–8.
• Boothman DA, Briggle TV, Greer S. Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. Pharmacol Ther. 1989;42:65–88.
• Özyürek H.A, Avcı G, Varol N. Gemsitabin uygulanan prostat kanseri hücre hatlarında oxaliplatin ve sisplatinin kemoterapötik etkilerinin belirlenmesi. Kocatepe Veterinary Journal. 2017;10:7-13.
• Demirci Ucsular F, Uslu O, Tuksavul F, Gulpek M, Kos T, Guclu S.Z. Küçük hücreli akciğer kanserinde gemsitabin-sisplatin kemoterapisinin etkinliği. Solunum. 2005;3:115-22.
• Öztürk N, Erbaycu A.E, Gülpek M, Tuksavul F, Uslu Ö, Güçlü S.Z, İleri ve lokal ileri evre küçük hücreli dışı akciğer kanserinde gemsitabin ve karboplatin kombinasyonu. Türk Onkoloji Dergisi. 2008;23:72-80.
• Aydın D, Sarıaydın M, Ünsal M. Gemsitabine bağlı kutanoz toksisite gelişen küçük hücreli dışı akciğer kanseri. İzmir Göğüs Hastanesi Dergisi. 2011;1:51-5.
• Sezgin V.C, Karabulut B, Uslu R, Şanlı U.A, Göker E. Daha önceden antrasiklin ve taksan tedavisi almış metastatik meme kanserli hastalarda gemsitabin tedavisi. Türk Hematoloji Onkoloji Dergisi. 2005;2:68-72.
• Çoban Z.D, Avcu F, Ural A.U, Kuzhan O, Güran Ş, Gemsitabinin multipl myelom (RPMI-8226) ve Ig G plazma hücreli lösemi (ARH 77) hücre hatları üzerindeki sitotoksik etkisi. Gülhane Tıp Dergisi. 2012;54:263-6.
• Altınel M, Arpalı E, Akıncı S, Sargın S, Yazıcıoğlu A. Gemsitabin-sisplatin kombinasyonu ile tedavi edilen ileri evre mesane tümörü hastalarının uzun dönem takip sonuçları. Turkiye Klinikleri J Urology. 2013;4:54-9.
• Yoo CB, Valente R, Congiatu C, Gavazza F, Angel A, Siddiqui MA et al. Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2′-deoxyzebularine. J Med Chem. 2008;51:7593–601.
• Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010;120:581–92.
• Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther. 2005;4:1505– 14.
• Schuebel K, Baylin S. In living color: DNA methyltransferase caught in the act. Nat Methods. 2005;2:736–38.
• Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65:6305–11.
• Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:7563–70.
• Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: Multiple mechanisms and endpoints for phase II trials. Nutr Rev. 2004;62:204–11.
• Chen D, Milacic V, Chen MS, Wan SB, Lam WH, Huo C et al. Tea polyphenols, their biological effects and potential molecular targets. Histol Histopathol. 2008;23:487–96.
• Taşlı B, Çiçek F, Demirtaş G, Yalçın E, Çavuşoğlu K. Formaldehit toksisitesine karşı yeşil çay özütünün koruyucu etkisi: swiss albino farelerde genotoksik değerlendirme. Fen Bilimleri Dergisi (CFD). 2015;36:63-73.
• Tosun İ, Karadeniz B. Çay ve çay fenoliklerinin antioksidan aktivitesi. OMÜ Ziraat Fakültesi Dergisi. 2005;20:78-83.
• Kelleci F, Sipahi H, Charehsaz M, Aydın A. Yeşil çay ve ilaç etkileşimleri. Türkiye Klinikleri Literatür Eczacılık Bilimleri Dergisi. 2013;2:85-92.
• Aydın S, Tokaç D, Başaran N, Başaran A, Effect of Epigallocatechin gallate on oxidative DNA damage in human lymphocytes. Türkiye Klinikleri Literatür Eczacılık Bilimleri Dergisi. 2015;12:19-28.
• Piña IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D et al. Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem. 2003;68:3866–73.
• Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M et al Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004;64:689–95.
• Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs. 2003;21:85–97.
• Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Annu Oncol. 2003;14:766–74.
• Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res. 2003;9:1596–603.
• Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005;5:44.
• Karaca Ö, Ertekin T, Canöz Ö, Hacıalioğulları M, Ekinci N, Elmalı F, Ülger H. 1,2-dimetilhidrazin ile Balb/C türü farelerde deneysel kolon kanserinin indüklenmesi. Turkiye Klinikleri Journal of Medical Sciences. 2010;30:1015-24.
• Çakan A, Erbaycu A, Dereli Ş, Özsöz A, Tüberküloz tedavisi ve hepatotoksisite. Tüberküloz ve Toraks Dergisi. 2000;48:259-65.
• Temel M. Sitotoksik kemoterapötiklerin yirminci yüzyıldaki gelişimi. Türk Onkoloji Dergisi. 2015;30:96-10.
• Torabi F, Dadkhah A, Dini S, Taghizadeh M, Malayeri M. Prevention and therapy of 1,2-dimethyl hydrazine induced colon carcinogenesis by Ferula assafoetida hydroalcoholic extract. Turkish Journal of Biochemistry. 2015;40:390-400.
• Günbatar N, Bayıroğlu F. Sıçanlarda yüksek oranda doymuş yağlı diyet ile aralıklı beslemenin deneysel kolon gelişimi ve bazı serum inflamasyon markırları üzerine etkisi 1 adiponektin ve lipid metabolizması. Van Veterinary Journal. 2015;26:123-7.
• Marsoni S, Damia G, Camboni G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics. 2008;3:164–71.
• Fang MH, Ji XM. Histone modification and its application in therapy for hematologic malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:816–20.
• Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A. 2010;107:20003–8.
• Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978;14:105-13.
• Cho HJ, Kim SY, Kim KH, Kang WK, Kim JI, Oh ST et al. The combination effect of sodium butyrate and 5-Aza-2′-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J Surg Oncol. 2009;7:49.
• İzmirli M. Epigenetik hastalıklar ve tedavi yaklaşımları. Hacettepe Tıp Dergisi. 2007;38:48-54.
• Kocatürk S, Kasap H, Koç F, Güzel A. Spinal müsküler atrofi ve moleküler genetiği. Arşiv Kaynak Tarama Dergisi. 2012;21:1-26.
• Man N, Humphrey E, Lam LT, Fuller HR, Lynch TA, Sewry CA et al. A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Neurology. 2008;71:1757–63.
• Canpolat M, Bayram AK, Bahadır O, Per H, Gümüş H, Dundar M et al. Spinal musküler atrofi olgularının klinik özellikleri. Günel Pediatri. 2016;14:18-22.
• Çetin M, Koçyiğit İ. Miyelodisplastik sendromlar. Turkiye Klinikleri J Int Med Sci. 2007;3:90-5.
• Tokatlı A. Doğuştan metabolik hastalıklara tanısal yaklaşım. Güncel Pediatri. 2006;4:1-10.
• Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S et al. Valproic aciddefines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–78.
• Travaglini L, Vian L, Billi M, Grignani F, Nervi C. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol. 2009;41:225–34.
• Kim SH, Kang HJ, Na H, Lee MO. Trichostatin A enhances acetylation as well as protein stability of ERα through induction of p300 protein. Breast Cancer Res. 2010;12:22.
• Li Y, Yuan YY, Meeran SM, Tollefsbol TO. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol Cancer. 2010;9:274.
• Çaldıran Y. Hidroksamik asit hidrojellerinin hazırlanması, karakterizasyonu ve uranyum tutunmasında kullanımı (Yüksek lisans tezi). Sivas, Cumhuriyet Üniversitesi, 1997.
• Çakmak A, Bazı substitue alifatik-aromatik amidlerin ve hidroksamik asitlerin in vitro mikrozomal metabolizmaları (Yüksek lisans tezi). İstanbul, Marmara Üniversitesi, 2007.
• Ertürk A. İlaç etken maddesi içeren yeni hidroksamik asitlerin ve metal komplekslerinin sentezi, karakterizasyonu ve bazı biyolojik aktivitelerinin incelenmesi (Yüksek lisans tezi) Rize, Recep Tayyip Erdoğan Üniversitesi, 2013.
• Çiçek E, Histon deasetilaz (HDAC) inhibitörü olan bazı hidroksamik asit türevlerinin bağlanma özelliklerinin moleküler kenetlenme yöntemiyle teorik olarak incelenmesi (Yüksek lisans tezi).Rize, Recep Tayyip Erdoğan Üniversitesi, 2017.
• Yüksek EH, İnsan kolanjiokarsinoma hücre hattında (TFK-1) saha uygulamasının E-kaderin, N- kaderin ve vimentin genleri üzerine etkisinin araştırılması (Yüksek lisans tezi). Kayseri, Erciyes Üniversitesi, 2017.
• Cihan C, Glioblastoma multiforme tümör hücrelerine karşı temozolomide ve suberoylanilide hydroxamic acid'in kombine/sinerjik tedavisinde apoptoz etkinliğinin araştirilmasi(Yüksek lisans tezi). İstanbul, Marmara Üniversitesi, 2012.
• Ulutürk TD, Histon deasetilaz 8 özgül inhibitörlerin ın-vitro araştırılması (Yüksek lisans tezi). Ankara, Hacettepe Üniversitesi, 2010.
• Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest. 2007;25:659–65.
• Xu WS, Perez G, Ngo L, Gui CY, Marks PA. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res. 2005;65:7832–39.
• Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005;11:6382–89.
• Im JY, Park H, Kang KW, Choi WS, Kim HS. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem Biol Interact. 2008;172:235–44.
• Park H, Im JY, Kim J, Choi WS, Kim HS. Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med. 2008;21:325– 33.
• Keles E, Lianeri M, Jagodziński PP. Apicidin suppresses transcription of 17β-hydroxysteroid dehydrogenase type 1 in endometrial adenocarcinoma cells. Mol Biol Rep. 2011;38:3355–60.
• Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem. 1993;268:22429–35.
• Monneret C. Histone deacetylase inhibitors. Eur J Med Chem. 2005;40:1–13.
• Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T et al. A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 2009;96:4592–97.
• Liu Y, Liggitt D, Fong S, Debs RJ. Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types. Gene Ther. 2006;13:1724–30.
• Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010;9:3254–66.
• Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp Ther Oncol. 2002;2:325–32.
• Ray A, Okouneva T, Manna T, Miller HP, Schmid S, Arthaud L et al. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res. 2007;67:3767–76.
• Xu J, Zhou JY, Wei WZ, Philipsen S, Wu GS. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008;68:6718–26.
• Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A. 2001;98:87–92.
• Riva L, Blaney SM, Dauser R, Nuchtern JG, Durfee J, McGuffey L et al. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin Cancer Res. 2000;6:994–7.
• Perabo FG, Müller SC. New agents for treatment of advanced transitional cell carcinoma. Annu Oncol. 2007;18:835–43.
• Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004;64:316–21.
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28:1069–78.
• Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol. 2009;625:131–42.